We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
Pharma group’s decision comes in response to US political pressure over high cost of diabetes medication
Health department says industry’s plan, published ahead of talks, would limit access to new medicines
UK pharma industry claims that de facto tax will hurt research and development investment
Specialist drugs sold by Big Pharma are so expensive that many patients are being excluded
Drugmaker taken to court by public interest group for abusing market position and profiteering
Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch
Tight budgets and US reforms are ending a truce between the industry and health authorities
Officials row with Pfizer over price as villages struggle to obtain antiviral medication
Beijing’s push to boost the sector has been undermined by reimbursement rules
UK and EU must balance health cost control with plans to grow life sciences
AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales
Demand for antiviral treatment has rocketed after jump in infections following Beijing policy U-turn
High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially
Move enables pharmacists to prescribe alternative formulations of antibiotics after rise in cases of Strep A
CSL’s $3.5mn single-dose treatment for haemophilia sparks debate over how to pay for revolutionary drugs
CMA acknowledges ‘real concerns’ over pricing of drugs but is yet to launch formal investigation
Health chiefs deny shortage of penicillin and amoxicillin following surge in infections
Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy
Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies
Agreement to limit the size of the NHS drugs bill under strain
US drugs maker also says low pricing of NHS purchases risks harming Britain’s push in life sciences
Groups say continuation of a scheme aimed at limiting NHS’s medicines bill will reduce or end their British operations
Makers of blockbuster drugs including Eli Lilly, AbbVie and AstraZeneca face new curbs
Competition and Markets Authority cuts £20mn from previous penalty after long legal battle
International Edition
